Other research studies have already demonstrated the efficacy of different MTDL’s in vivo in AD but with different action mechanisms such as CHF5074 (anti-inflammatory and γ-secretase inhibitor)25, ARN14140 (NDMA and AChE)26; MT-031 (MAO-A and AChE/BuChE inhibitor)27; M30 (propargylamine and chelating)28. The gene discussed is MAOA; the disease is Alzheimer disease.